Spain's rare kidney disease experts seek faster diagnosis and equitable treatment access

In a conference room in Seville, doctors, hospital administrators, and patients gathered to talk about something most people have never heard of: rare kidney diseases that arrive quietly, often too late. The conversation centered on complement 3 glomerulopathy, or C3G, a condition so uncommon that many primary care physicians never see it, yet devastating enough that half of those diagnosed will need dialysis within a decade.

The Hospital Universitario Virgen del Rocío, where the discussion took place, has become a center of expertise for these invisible illnesses. Nieves Romero, the hospital's director, framed the challenge plainly: public health systems exist to serve everyone, but rare diseases demand something special—sustained investment in knowledge, infrastructure, and people. The hospital holds 39 officially recognized specialized centers, with five more under evaluation and eight in preparation. Yet maintaining that excellence costs more than money. "You need a sufficient patient population, a high level of expertise, and you have to care for the professionals who make it possible," Romero said. "Sometimes the contracts and mobility frameworks don't help you keep the talent."

The first wall patients hit is diagnosis itself. Verónica López, head of nephrology at the Regional Hospital of Málaga, described the problem with clinical precision: C3G presents in wildly different ways—blood in the urine, protein in the urine, high blood pressure—so when a patient arrives at a primary care clinic, the disease often goes unrecognized. By the time someone thinks to test for it, weeks or months have passed. The condition then requires not just a kidney biopsy but genetic studies, each step adding delay. "If you don't think of it, the referral gets delayed and the patient arrives at our door in advanced stages," López explained.

Once diagnosed, the therapeutic landscape is bleak. About 6 percent of rare diseases have any treatment at all. For C3G, the numbers are grim: roughly 50 percent of patients reach dialysis within ten years. In children, the disease is more aggressive—70 to 80 percent need dialysis or transplant by age ten. Even transplantation offers no escape. The disease recurs in 80 to 90 percent of transplant recipients, sending patients back to the beginning. Francisco de la Cerda, head of pediatric nephrology at Virgen del Rocío, described the emotional weight: "Telling a family their child has a rare disease with an almost unpronounceable name, that they can't locate anywhere—it generates enormous anxiety."

Transplantation itself presents a separate crisis. Domingo Daga, Andalusia's transplant coordinator, noted a paradox: it is now easier to transplant an organ into an elderly patient than a young one. Finding an optimal deceased-donor kidney for someone under fifty has become increasingly difficult. Spain has made progress—the average wait time from listing to transplant in Andalusia is three to four months—but the system still needs to expand living-donor transplantation, an area where Spain has considerable room to improve.

The pharmaceutical industry faces its own constraints. Last year, Spain launched more than 200 clinical trials for rare diseases, enrolling over 3,600 patients—a 10 percent increase from the previous year. Yet the timeline remains punishing: developing a drug for a rare disease takes ten to twelve years on average, and after European approval, Spain takes nearly two years to fund it. "We're using exceptional access pathways designed for very specific situations just to compensate for that delay," said Raquel Fernández, deputy director of institutional relations at Sobi España.

Hospital pharmacists have become essential gatekeepers. Alberto Jiménez, head of pharmacy at Hospital Virgen de las Nieves in Granada, described the sudden arrival of orphan drugs: "Many treatments for rare diseases burst into hospital pharmacy overnight, and suddenly we're managing a disease we've barely interacted with." His team created clinical commissions to evaluate evidence and facilitate access to expanded-use programs and compassionate-use pathways. The key insight is economic: a drug that prevents dialysis or a second transplant may cost more upfront but saves the system far more in long-term care.

From the patient perspective, dialysis remains the symbol of advanced kidney disease's brutality. Four-hour sessions, three days a week, often requiring travel by ambulance from distant towns. Pablo Beca, president of ALCER Giralda and a transplant recipient for nearly 22 years, described how patient associations cushion that impact through psychological support, mutual-aid groups, and activities—weekend excursions on the one day without dialysis, camps for children, coordinated travel to dialysis centers across Europe. Despite the weight of these conditions, the room held a measured optimism. "We're living in a very good time for nephrologists," López said. "Glomerular diseases that once had only supportive treatments are beginning to have specific drugs." The collective goal is clear: accelerated access pathways that allow patients to receive treatment while real-world data accumulates, reducing both human suffering and long-term system costs.